TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36206441

Group type: EXPERIMENTAL
Intervention: Variational entanglement-assisted quantum process tomography with arbitrary ancillary qubits.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Silicon photonic chip implementation of the method.
Number of subjects: 8
Study: 34679211

Group type: EXPERIMENTAL
Intervention: 3-month lifestyle intervention using a mobile app and a wearable device
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Average TST of 4.0-5.3 hours
Number of subjects: 173
Study: 32333159

Group type: EXPERIMENTAL
Intervention: Preferred music exposure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active noise-cancelling headphones
Number of subjects: 60
Study: 35940001

Group type: EXPERIMENTAL
Intervention: Crisis Line Facilitation (CLF) intervention
Number of subjects: 307

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 307
Study: 34936270

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with wheat-grain moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral sertraline hydrochloride dispersible tablets, 50 mg once a day
Number of subjects: 60
Study: 35943472

Group type: EXPERIMENTAL
Intervention: Stenting plus medical therapy (n=176)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Medical therapy alone (n=182)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Stenting plus medical therapy (n=171)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Medical therapy alone (n=178)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Stenting plus medical therapy (n=168)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Medical therapy alone (n=170)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Stenting plus medical therapy (n=160)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Medical therapy alone (n=159)
Number of subjects: 380
Study: 34341340

Group type: EXPERIMENTAL
Intervention: Variations in headline and image 'package' used in A/B tests.
Number of subjects: 538272878

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 538272878
Study: 35434041

Group type: EXPERIMENTAL
Intervention: L. plantarum Lp3a; 2×1.0×10^10 CFU for 7 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 120
Study: 32241625

Group type: EXPERIMENTAL
Intervention: Virtual reality meditation for 30 minutes using a head‐mounted display on the evening of the admission day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Virtual reality meditation
Number of subjects: 48
Study: 616774454

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 35810275

Group type: EXPERIMENTAL
Intervention: Oropharyngeal regurgitation scenario
Number of subjects: 54

Group type: COMPARATOR
Intervention: Clean airway scenario
Number of subjects: 54
Study: 32994531

Group type: EXPERIMENTAL
Intervention: Medium cut-off (MCO) dialyzer
Number of subjects: 49

Group type: COMPARATOR
Intervention: High-flux group
Number of subjects: 49
Study: 35198149

Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 34497646

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100000 epinephrine
Number of subjects: 102

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:80000 epinephrine
Number of subjects: 102
Study: 33901574

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic optimization arm (varenicline for fast metabolizers, nicotine patch for slow metabolizers)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Adherence counseling arm (Managed Problem Solving - MAPS)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Control group (varenicline)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Control group (standard counseling)
Number of subjects: 488
Study: 32538028

Group type: EXPERIMENTAL
Intervention: Population size estimation of PWID
Number of subjects: 250
Study: 34296374

Group type: EXPERIMENTAL
Intervention: Pivotal response treatment (PRT), conducted three times a week for 2 months, totaling 24 one-hour sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 33927229

Group type: EXPERIMENTAL
Intervention: HemoCue
Number of subjects: 0

Group type: COMPARATOR
Intervention: DBS
Number of subjects: 0
Study: 33305625

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation with lavender oil scents
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vestibular rehabilitation without lavender oil scents
Number of subjects: 40
Study: 33757620

Group type: EXPERIMENTAL
Intervention: Building Healthy Children (BHC) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Community Standard
Number of subjects: 0
Study: 33402625

Group type: EXPERIMENTAL
Intervention: Magic trick distraction technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mobile dental game distraction technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: TSD (tell-show-do) technique
Number of subjects: 60
Study: 35915567

Group type: EXPERIMENTAL
Intervention: Active tDCS (5 x 7 cm2, 2 mA, 20 min, anode/cathode over the F4/Fp1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 60
Study: 33649113

Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35500453

Group type: EXPERIMENTAL
Intervention: 3-day high-fat diet (500 mL of cream, 1700 kcal)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 9
Study: 34336612

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 30
Study: 34313687

Group type: EXPERIMENTAL
Intervention: Hospital and postdischarge quality improvement intervention
Number of subjects: 5647

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5647
Study: 32532313

Group type: EXPERIMENTAL
Intervention: WhatsApp-delivered education programme (health promotion pamphlet and education materials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health promotion pamphlet (control group)
Number of subjects: 0
Study: 36278776

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 70
Study: 34666728

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg every night at bedtime
Number of subjects: 73

Group type: COMPARATOR
Intervention: Pumpkin seed oil 360 mg twice a day
Number of subjects: 73
Study: 34252115

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS)
Number of subjects: 117405

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) short-term use (<365 days)
Number of subjects: 117405

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) long-term use (>364 days)
Number of subjects: 117405

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) use in men
Number of subjects: 117405

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) use in women
Number of subjects: 117405

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) use in individuals over 70 years
Number of subjects: 117405

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) use in individuals under 70 years
Number of subjects: 117405

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) use in individuals at intermediate cardiovascular risk
Number of subjects: 117405

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) use in individuals at high cardiovascular risk
Number of subjects: 117405

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) use in individuals at low cardiovascular risk
Number of subjects: 117405

Group type: EXPERIMENTAL
Intervention: Glucosamine
Number of subjects: 117405
Study: 32763240

Group type: EXPERIMENTAL
Intervention: SER-287 after vancomycin preconditioning (daily dosing)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (placebo/placebo group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: SER-287 (weekly dosing)
Number of subjects: 58

Group type: COMPARATOR
Intervention: SER-287 (weekly dosing after vancomycin)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SER-287 (all SER-287 groups)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Vancomycin/SER-287 groups
Number of subjects: 58
Study: 32165550

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation content plus additional pain module delivered by a smartphone app
Number of subjects: 14

Group type: COMPARATOR
Intervention: Muscle relaxation content from the same app (active control)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care (passive control)
Number of subjects: 14
Study: 35398585

Group type: EXPERIMENTAL
Intervention: Natural cesarean delivery
Number of subjects: 191

Group type: COMPARATOR
Intervention: Traditional cesarean delivery
Number of subjects: 191
Study: 32795987

Group type: EXPERIMENTAL
Intervention: Improved access to postpartum family planning services including a brochure, up to 6 home visits from trained family planning counselors, free transportation to a family planning clinic, and financial reimbursement for services.
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: Intervention arm (n=1026)
Number of subjects: 2143

Group type: COMPARATOR
Intervention: Control arm (n=1117)
Number of subjects: 2143
Study: 33569973

Group type: COMPARATOR
Intervention: Candidates with no stereotypical attribute (CPX)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Candidates with purple hair (CPH)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Candidates with tattoos (CPT)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Candidates with a Liverpool English accent (CPA)
Number of subjects: 98
Study: 32873473

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone (usually levofloxacin) monotherapy, 54% of treatments in both settings
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Ceftriaxone monotherapy
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Antimicrobials for more than 7 days
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Respiratory rate >25 breaths per minute
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Being on hospice
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Not having dementia
Number of subjects: 395

Group type: COMPARATOR
Intervention: Hospitalization status
Number of subjects: 395
Study: 36208978

Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®)
Number of subjects: 0
Study: 34058173

Group type: EXPERIMENTAL
Intervention: Task-Switch (TS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-Task (DT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 32174580

Group type: EXPERIMENTAL
Intervention: Single-site phacotrabeculectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Twin-site phacotrabeculectomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Single-site and Twin-site)
Number of subjects: 40
Study: 34850428

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine spray
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 0.1% pH‐balanced chlorine dioxide spray
Number of subjects: 228

Group type: COMPARATOR
Intervention: Sterile water spray (placebo control)
Number of subjects: 228
Study: 32119662

Group type: EXPERIMENTAL
Intervention: Intention to donate blood
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Direct perceived behavioral control
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Direct subjective norm
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Direct attitude
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Past behavior of blood donation
Number of subjects: 515
Study: 33726853

Group type: EXPERIMENTAL
Intervention: Positive thinking training program (16 hours based on materials by Martin Seligman)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual programs (Control group)
Number of subjects: 78
Study: 35474448

Group type: EXPERIMENTAL
Intervention: 1-cm interval subcuticular sutures
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2-cm interval subcuticular sutures
Number of subjects: 50
Study: 33277277

Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 381
Study: 34547400

Group type: EXPERIMENTAL
Intervention: Intravenous injection of lipopolysaccharide (LPS) at a dose of 0.6 ng/kg body weight
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 49
Study: 33524145

Group type: COMPARATOR
Intervention: Nicotinamide Riboside (NR) supplementation at 1000 mg/day for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR) at 50 µM or 500 µM in vitro
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR) supplementation in HFD-fed mice at 400 mg/kg/day for 4 weeks
Number of subjects: 0
Study: 32340781

Group type: EXPERIMENTAL
Intervention: Optical Frequency Domain Imaging (OFDI) guidance in percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravascular Ultrasound (IVUS) guidance in percutaneous coronary intervention (PCI)
Number of subjects: 0
Study: 616493060

Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) supplementation (140ml of NO3‐rich beetroot juice containing 8.0mmol [NO3‐]) for seven days
Number of subjects: 9
Study: 35466449

Group type: EXPERIMENTAL
Intervention: Calcium Citrate (Ca-Cit)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Calcium Carbonate (CaCO3)
Number of subjects: 24
Study: 33760791

Group type: EXPERIMENTAL
Intervention: Liver machine perfusion (MP)
Number of subjects: 0
Study: 36307361

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 33893066

Group type: EXPERIMENTAL
Intervention: 1.5-T fast MRI (n = 213)
Number of subjects: 311

Group type: COMPARATOR
Intervention: mpMRI (n = 98)
Number of subjects: 311
Study: 33424487

Group type: EXPERIMENTAL
Intervention: Health communication channels for hepatitis B virus management
Number of subjects: 600
Study: 34467477

Group type: EXPERIMENTAL
Intervention: Different boron concentrations in the substrate
Number of subjects: 0
Study: 33517160

Group type: EXPERIMENTAL
Intervention: MRI reading by skilled musculoskeletal radiologists
Number of subjects: 20
Study: 35078552

Group type: EXPERIMENTAL
Intervention: Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C)
Number of subjects: 9
Study: 33095715

Group type: EXPERIMENTAL
Intervention: PK-clustering approach with visual analytics user interface
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional clustering algorithms (implied control)
Number of subjects: 0
Study: 35512731

Group type: EXPERIMENTAL
Intervention: 1-week break from social media
Number of subjects: 154

Group type: COMPARATOR
Intervention: Continue to use social media as usual
Number of subjects: 154
Study: 33370165

Group type: COMPARATOR
Intervention: Salacia chinensis extract (150, 300, or 600 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salacia chinensis extract (600 mg/day)
Number of subjects: 0
Study: 36484021

Group type: EXPERIMENTAL
Intervention: Loxoprofen Sodium Cataplasm combined with extracorporeal shock wave therapy (ESWT) and transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Loxoprofen Sodium Cataplasm alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physiotherapy alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Flurbiprofen Cataplasm combined with physiotherapy
Number of subjects: 100
Study: 36126105

Group type: EXPERIMENTAL
Intervention: Test 1 (diffusion optics lenses)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Test 2 (diffusion optics lenses)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control lenses
Number of subjects: 256
Study: 33867500

Group type: EXPERIMENTAL
Intervention: Land walking
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Water walking
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combined exercise groups
Number of subjects: 63
Study: 35215461

Group type: EXPERIMENTAL
Intervention: Nutrition and exercise intervention (bi‐weekly counselling for individualized energy and high dairy protein diet; walking goal of 10,000 steps/day)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Nutrition and exercise intervention
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 241
Study: 33231839

Group type: EXPERIMENTAL
Intervention: Chorion membrane (CM)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Chorion membrane (CM) + platelet rich fibrin (PRF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 32758298

Group type: EXPERIMENTAL
Intervention: Intravenous melatonin (IVM) 5 mg/kg/day for 7 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo 5 mg/kg/day for 7 days
Number of subjects: 18
Study: 35278402

Group type: EXPERIMENTAL
Intervention: Etrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33267815

Group type: EXPERIMENTAL
Intervention: Typical Dialysis (TD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Typical Dialysis + Exercise (TD + E)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cold Dialysis (CD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cold Dialysis + Exercise (CD + E)
Number of subjects: 10
Study: 34554015

Group type: EXPERIMENTAL
Intervention: Optimal allocation to treatments in a sequential multiple assignment randomized trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximin optimal design methodology
Number of subjects: 0
Study: 32077706

Group type: EXPERIMENTAL
Intervention: Label as 'client'
Number of subjects: 526

Group type: COMPARATOR
Intervention: Label as 'patient'
Number of subjects: 526

Group type: COMPARATOR
Intervention: Label as 'consumer'
Number of subjects: 526

Group type: COMPARATOR
Intervention: Label as 'service user'
Number of subjects: 526
Study: 34091468

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Steroid Injection
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Short-Form Health Survey
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dallas Pain Questionnaire
Number of subjects: 34
Study: 34940059

Group type: EXPERIMENTAL
Intervention: Suppressive doses of levothyroxine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: TSH concentration <0.1 µU/mL
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: TSH concentration 0.4‐4.0 µU/mL
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: TSH concentration 0.1‐0.39 µU/mL
Number of subjects: 98

Group type: COMPARATOR
Intervention: Overall findings
Number of subjects: 98
Study: 32728920

Group type: EXPERIMENTAL
Intervention: NAMI Provider Education Program - a 15-h contact-based adjunctive curriculum
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 231
Study: 34036235

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (Bev plus CTx)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (CTx) alone
Number of subjects: 132
Study: 32272024

Group type: EXPERIMENTAL
Intervention: sweetened-milk (FED)
Number of subjects: 14

Group type: COMPARATOR
Intervention: water control (FAST)
Number of subjects: 14
Study: 35077429

Group type: EXPERIMENTAL
Intervention: Perforating fat injections (2.6 ± 1.6 ml of fat injected per foot at one to two sites)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Perforating fat injections
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (observed for 6 months, injected, and then followed for 6 months)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 34149004

Group type: EXPERIMENTAL
Intervention: 5‐FU/leucovorin
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: epirubicin/cisplatin/5‐FU
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 5‐FU chemoradiation
Number of subjects: 281
Study: 32295531

Group type: EXPERIMENTAL
Intervention: BCM group (bioimpedance guided dry weight assessment)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: BCM group
Number of subjects: 445
Study: 35172875

Group type: EXPERIMENTAL
Intervention: Decision aid intervention
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 310
Study: 33378139

Group type: EXPERIMENTAL
Intervention: Pretomanid 400 mg
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pretomanid 1000 mg
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pretomanid 400 mg plus Moxifloxacin 400 mg
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 33025342

Group type: EXPERIMENTAL
Intervention: Ozanimod (0.23 mg on days 1-4, 0.46 mg on days 5-7, 0.92 mg on days 8-10, and 1.84 mg on days 11-30) + Pseudoephedrine (PSE) 60 mg on day 30
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo + Pseudoephedrine (PSE) 60 mg on day 30
Number of subjects: 56
Study: 33839753

Group type: EXPERIMENTAL
Intervention: Mechanical and oral antibiotic bowel preparation (MOABP)
Number of subjects: 381

Group type: COMPARATOR
Intervention: No bowel preparation (NBP)
Number of subjects: 381
Study: 33327255

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0
Study: 35476749

Group type: EXPERIMENTAL
Intervention: Yoga-based lifestyle intervention (3-month program, 3 one-hour sessions per week)
Number of subjects: 96
Study: 35543479

Group type: EXPERIMENTAL
Intervention: Self-management program based on 5 A's model
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 96
Study: 35304275

Group type: COMPARATOR
Intervention: Low dose Cassia seed powder (0.3 g once daily)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: High dose Cassia seed powder (3.0 g once daily)
Number of subjects: 94